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Abstract
Background and objectives
Adverse events (AEs) associated with the use of fluoroquinolone antimicrobials include
Clostridium difficile associated diarrhea (CDAD), liver injury and seizures. Yet, the economic
impact of these AEs is seldom acknowledged. The aim of this review was to identify health
service use and subsequent costs associated with ciprofloxacin, levofloxacin, moxifloxacin,
norfloxacin and ofloxacin -related AEs.
Methods
A literature search covering Medline, SCOPUS, Cinahl, Web of Science and Cochrane
Library was performed in April 2017. Two independent reviewers systematically extracted
the data and assessed the quality of the included studies. All costs were converted to 2016
euro in order to improve comparability.
Results
Of the 5,687 references found in the literature search, 19 observational studies, of which
five were case-controlled, fulfilled the inclusion criteria. Hospitalization was an AE-related
health service use outcome in 17 studies. Length of hospital stay associated with AEs varied
between <5 and 45 days. The estimated cost of an AE episode ranged between 140 and
18,252 €. CDAD was associated with the longest stays in hospital. Ten studies reported AE-
related length of stays and five evaluated costs associated with AEs. Due to the lack of pub-
lished literature, health service use and costs associated with many high-risk FQ-related
AEs could not be evaluated.
Conclusions
Because of the wide clinical use of fluoroquinolones, in particular serious fluoroquinolone-
related AEs can have substantial economic implications, in addition to imposing potentially
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devastating health complications for patients. Further measures are required to prevent and
reduce health service use and costs associated with fluoroquinolone-related AEs. Equally,
better-quality reporting and additional published data on health service use and costs asso-
ciated with AEs are needed.
Introduction
Fluoroquinolones (FQs) are counted among broad-spectrum antimicrobials and are used to
treat genitourinary, respiratory, gastrointestinal, skin and soft tissue infections[1]. FQs are gen-
erally well tolerated antimicrobials: the discontinuation of treatment due to AEs is required in
fewer than five percent of consumption[2]. Their mechanism of action is based on the drugs’
ability to inhibit DNA gyrase and topoisomerase IV, and thus, DNA synthesis[3]. The most
common AEs are mild and reversible, such as diarrhea, nausea and headaches. However, FQs
are also associated with more serious AEs, including Clostridium difficile infections, prolonged
QT interval, tendinitis and tendon rupture, dysglycemia, hepatic toxicity, phototoxicity, acute
renal failure and serious AEs involving the central nervous system, such as seizures. [4] [1] FQ-
related AEs can be multisymptomatic, progressive and have long latency periods, which can
make them difficult to detect[5]. FQs have been in clinical use since the 1980s[6] and are glob-
ally among the most consumed antimicrobials[7]. Due to reported serious AEs associated with
the use of FQs, the European Medicines Agency (EMA) recommended restrictions on their use
in October 2018.[8] The U.S. Food and Drugs Administration (FDA) has issued several “black
box warnings” against FQs with the latest safety announcement dated in December 2018 warn-
ing about an increased risk of ruptures or tears in the aorta blood vessel in some patients.[9]
FDA-approved FQs are ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin, gemifloxacin and
recently, delafloxacin[10][11]. FQs approved in Europe include ciprofloxacin, levofloxacin,
moxifloxacin, ofloxacin, gemifloxacin, cinoxacin, enoxacin, flumequine, lomefloxacin, nalidixic
acid, norfloxacin, pefloxacin, pipemidic acid, prulifloxacin and rufloxacin.
The economic burden of AEs is substantial and in direct relation to current increasing drug
utilization. According to previous research, the annual cost of AEs in the U.S. may be as high
as 22.9 billion euros [12]. In Europe AEs are considered to contribute to 3.6 percent of hospital
admissions, have an impact on 10 percent of inpatients during their hospital admission and
are responsible for almost 0.5 percent of inpatient deaths. [13] AEs thus clearly constitute a
major clinical issue. Prescribing a drug is always a conflict of benefits set against harms deci-
sion, weighing the risk of morbidity and even mortality from the disease against similar effects
from AEs and added health care costs. Unfortunately, a thorough understanding of the signifi-
cance of AEs and the benefit-risk-ratio of drug treatments can only be acquired through long-
term clinical use after marketing authorization and subsequent research. Health service use
and costs specifically associated with FQ-related AEs have not been evaluated previously.
The aim of our study was to identify health service use and health service costs associated
with ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin and ofloxacin -related AEs.
Methods
Literature search
A systematic literature search was performed in April 2017 covering Medline, SCOPUS,
CINAHL, Web of Science and Cochrane Library. A library information specialist was
FQ-related AEs resulting in health service use and costs
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consulted in forming the search strategies, which consisted of search terms relating to FQs,
AEs, health service use and costs. The Web of Science -database search included several con-
ference papers, which could be used to find unpublished literature and reduce publication
bias. Finally, literature references of the included articles were sourced to identify potentially
relevant articles. The search strategy for Medline can be found in S1 File. In this systematic
review, AEs are defined as medical occurrences temporally associated with the use of a medici-
nal product, but not necessarily causally related. A serious adverse event, on the other hand, is
defined as any untoward medical occurrence that at any dose either results in death, is life
threatening, requires inpatient hospitalization or prolongation of existing hospitalization or
results in persistent or significant disability or incapacity. [14] Health service use is referred to
as services provided to individuals or communities by health service providers for the purpose
of promoting, maintaining, monitoring or restoring health[15]. Costs presented in this study
comprise resources consumed due to health service use.
Study selection
References identified in the literature search were imported to reference management software
(Mendeley) and duplicates were removed. Only references that met previously fixed PICOS
(patients, intervention, control, outcome, setting) [16] criteria, were included in the review.
There were no limitations concerning publication year. The PICOS framework is depicted in
Table 1.
Both reviewers (LK, KV) individually screened the articles based on title and excluded dis-
tinctly irrelevant references such as literature regarding topical ophthalmic FQs. A third author
(MB) was available to resolve possible discrepancies. The remaining articles were screened
based on abstracts and full texts. The number of identified, included and excluded references
are depicted in the flow chart.
Data collection
The data of the included articles was extracted into two spread sheets (Microsoft Excel). The
usefulness of the tables was tested with a total of eight articles, after which minor adjustments
were made regarding the reporting of fatalities. Both reviewers (LK, KV) filled in both tables
independently. The first table contains characteristics of the included studies, such as authors,
publication years, aims, patient details, study designs, durations, follow-ups, funding details
and publications. The second table summarizes results covering specifics of the fluoroquino-
lone associated with the adverse event, adverse event types, health service use, length of hospi-
tal stay, AE costs and possible fatalities. In order to improve comparability, all the reported
costs were converted to euro by using the exchange rate of the European Central Bank and
Table 1. Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
Patient Adults (� 16-year old patients) Children (< 16-year old patients) Animals
Intervention Single systemic use of levo-, cipro-, moxi-, nor-,
or ofloxacin
Other intervention, FQ as a part of combination
therapy or not systemic use
Comparison Other intervention, placebo, no comparison -
Outcome Levo-, cipro-, moxi-, nor-, oflo-related AE
resulting in health service use and/or costs
No reported levo-, cipro-, moxi-, nor-, oflo-
related AE health service use and/or costs
Study
design
RCT, observational studies Case reports, case series
Published only as abstract
No English full-text
https://doi.org/10.1371/journal.pone.0216029.t001
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adjusted to the price level of the year 2016 using the value of money index of Statistics Finland
[17][18].
Quality assessment
The quality of the included studies was assessed according to the STROBE checklist for obser-
vational studies.[19] The studies were awarded scores, which are presented in percentages.
Two reviewers (LK, KV) assessed the quality of the included studies independently. The level
of agreement between the reviewers was 93%.
Results
Search results
In all, 4,454 unique references were identified in the literature search (Fig 1). Screening based
on titles excluded 4,217 references. Two hundred and twenty full-text articles did either not
meet the inclusion criteria (n = 208 studies), were found to be duplicates (n = 8) or lacked an
English language full-text (n = 4). After two additional studies were found in literature refer-
ences, a total of 19 studies were included in this systematic review. The list of the excluded arti-
cles is displayed in S2 File.
Study characteristics
Of the 19 included observational studies ([20]-[31]), five were case-controlled ([20][21][22]
[23][24]). The studies were published between 2002 and 2017. There were substantial differ-
ences in study duration, the length varied from 4 weeks to 22 years. The total sample size of
the included studies comprised 1,752,544 patients. During the study periods, 33,477 AEs that
were identified as FQ-related occurred. The studies included 22,704 AEs associated with levo-
floxacin, 339 with ciprofloxacin, two with norfloxacin, three with ofloxacin and 168 with moxi-
floxacin. In total, 10,773 AEs were associated with an unspecified FQ. A total of 26,893 (80%)
were identified from one study[25]. The average age of all total sample was 60,8 years and
50,71% were men. Only one study explicitly involved a cohort of patients with comorbidities
(diabetes).[26] The characteristics of the included studies are summarized in Table 2.
Health service use
Although the search covered all AEs related to FQs, the AEs depicted in the included studies
can mostly be defined as serious, since hospitalization was the most frequently reported AE-
related health service use (17 studies [20]-[30][25]-[35][36][37]). Hospitalization was required
in all CDAD -cases and serious cutaneous AEs. McFarland et al. provided the most detailed
report of health service use relating to CDAD. In the study 30 percent of CDAD -patients were
admitted to an ICU, two percent required surgical intervention and 21 percent were readmit-
ted to a health care facility [22]. The specific number of hospitalized patients was not detailed
in the included studies. Fatalities were reported in several studies ([20][24][28][32][35]-[37]).
However, none of the fatalities were directly associated with FQs. FQ-related cutaneous AEs
were highlighted specifically in studies of Asian origin ([30][33][37]).
In addition, emergency department (ED) visits were reported in four studies ([21][26][38]
[29]). Length of hospital stay was reported in 10 studies ([20][22][24][26] [30][32][34][35][36]
[37]) and varied between <5 and 45 days. Long hospital stays were particularly associated with
CDAD.
FQ-related AEs resulting in health service use and costs
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Costs
AE-related costs were evaluated and reported in only five studies ([23][25][32][35][29]) and
the disparity between estimations was significant. The cost of an AE-related episode varied in
this systematic review between 140 and 18,252 € and there was also considerable variation
among AE episodes within some individual studies. Llop, for example, evaluated the cost of an
average FQ-related AE episode to be 4,528±18,252 € [25]. In this systematic review, the highest
reported health care costs were associated with CDAD, and costs associated with other AEs
were not specified. In four studies, costs were evaluated from the perspective of the hospital
Fig 1. Flow chart of the study selection process.
https://doi.org/10.1371/journal.pone.0216029.g001
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Table 2. Characteristics of the studies (n = 19) included in the current review.
Study, Year of
publication,
Country
Aim of the Study Patients Study design Study
duration
Follow-
up to AE
Source of research
funding
Journal
Case-controlled
studies
Dhalla et al.
2006, Canada
[20]
To determine if
community-acquired
CDAD was more strongly
associated with gati and
moxi than with levo
Cases: Patients (n = 96,
mean age, years 80, IQR
76–84, male sex 44.8%)
with a prescription for
levo, moxi, gati or cipro
admitted to hospital with
a diagnosis of CDAD.
Controls: Patients with a
prescription for levo,
cipro, gati or moxi with
no hospitalization
involving CDAD
(n = 941, mean age, years
80, IQR 75–83, male sex
44.3%)
Population-based,
nested case-control
study
3 years 30 days Canadian Institutes for
Health Research
Antimicrobial Agents and
Chemotherapy
Kaye et al. 2014,
USA [21]
To estimate the incidence
and relative risk of a
hospitalization or
emergency visit for
noninfectious liver injury
in users of eight oral
antimicrobials—
amoxicillin, amoxicillin-
clavulanic acid
clarithromycin,
cefuroxime, doxycycline,
levo, moxi, telithromycin
—compared with
nonusers of these
antimicrobials
Cases: Patients (n = 607,
mean age, years 56.5,
male sex 45%) with or
without antimicrobial
exposure and subsequent
diagnosis indicating
noninfectious liver injury.
Controls: Patients
(n = 6070, mean age,
years 56.1, male sex 45%)
with or without
antimicrobial exposure
without subsequent
diagnosis indicating
noninfectious liver injury.
Retrospective
observational cohort
study with nested
case-control analysis
7 years 9
months
30 days
and 90
days
Bayer Pharma AG Pharmacotherapy
McFarland et al.
2007, USA [22]
To test the hypothesis that
the increase in CDAD
incidence was associated
with the formulary change
of replacing levo with gati,
and to determine CDAD
risk factors for the study
population
Cases: Inpatients
(n = 164, mean age,
years ± SD 65.9 (13.4),
male sex NR) and
outpatients (n = 20, mean
age, years ± SD 56.5
(48.5), male sex NR) with
CDAD. Controls:
inpatients and outpatients
without CDAD (n = 184,
mean age, years ± SD NR,
male sex NR)
Retrospective,
matched case-control
study
Unclear 3
months
The Seattle
Epidemiologic Research
and Information Center
Clinical Infectious
Diseases
Muto et al. 2005,
USA [23]
To identify risk factors for
Clostridium difficile
acquisition and
characterize the outbreak
Cases: Patients admitted
to hospital with CDAD
(n = 203, median age,
years (range) 64 (17–95),
male sex 51.2%) Controls:
Patients admitted to
hospital without CDAD
(n = 203, median age,
years (range) 59 (16–93),
male sex 52.2%)
Retrospective case-
control study
1 year 4
months
28 days The National Institute
of Allergy and
Infectious Diseases
Infection Control and
Hospital Epidemiology
(Continued)
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Table 2. (Continued)
Study, Year of
publication,
Country
Aim of the Study Patients Study design Study
duration
Follow-
up to AE
Source of research
funding
Journal
Paterson et al.
2012, Canada
[24]
To explore the association
of FQ use with subsequent
admission to hospital for
acute hepatotoxicity
Cases: Patients with no
history of liver disease
admitted to hospital with
acute liver injury, prior
use of broad-spectrum
antibiotics (n = 144,
mean age, years ± SD 77.4
(7.9), male sex 52.8%)
Controls: Patients with
no acute liver injury
subsequent to broad-
spectrum antibiotic use
(n = 1409, mean age,
years ± SD 77.0 (7.5),
male sex 52.4%)
Population-based,
nested, case-control
study
9 years 30 days The Canadian Institutes
of Health Research and
The Institute for
Clinical Evaluative
Sciences
Canadian Medical
Association Journal
Cohort studies
Aspinall et al.
2009, USA [27]
To compare the risk of
severe hypo- and
hyperglycemia in a cohort
of patients treated with
gati, cipro, or levo or with
a non-FQ antibiotic,
azithromycin
Outpatients with a
prescription for gati
(n = 218,748, mean
age ± SD, years 62.9
(13.8), male sex 93.7%),
levo (n = 457,994, mean
age ± SD, years 63.5
(13.5) male sex 94.2%),
cipro (n = 197,940, mean
age ± SD, years 62.8
(13.6), male sex 93.7%) or
azithromycin
(n = 402,566, mean
age ± SD, years 58.2
(14.7), male sex 89.5%)
Retrospective
inception cohort study
5 years 15 days The Veterans Affairs
Center for Medication
Safety
Clinical Infectious
Diseases
Chou et al. 2013,
Taiwan [26]
To assess the risk of severe
dysglycemia among
diabetic patients who
received different FQ
Diabetic patients with
new prescriptions for oral
cipro (n = 12,564, mean
age ± SD, years 66.4
(13.2), male sex 42.2%),
levo (n = 11,766, mean
age ± SD, years 67.0
(12.8), male sex 48.4%),
moxi (n = 4,221, mean
age ± SD, years 67.6
(13.0), male sex 57.1%),
second-generation
cephalosporins
(n = 20,317, mean
age ± SD, years 62.4
(14.2), male sex 41.7%) or
macrolides (n = 29,565,
mean age ± SD, years 62.4
(12.6), male sex 52.0%)
Population-based
inception cohort study
1 year 11
months
30 days The Taiwan
Department of Health
Clinical Infectious
Diseases
Mah et al. 2011,
USA [28]
To examine how age and
levo exposure influence
the absolute risk of CDI in
an academic medical
center
Patients exposed to levo
(n = 2,636, age 20–99
years, male sex % NR) or
ceftriaxone (n = 1,267,
age 20–99 years, male sex
% NR)
Retrospective cohort
study
2 years 30 days No funding to disclose Infectious Diseases in
Clinical Practice
(Continued)
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Table 2. (Continued)
Study, Year of
publication,
Country
Aim of the Study Patients Study design Study
duration
Follow-
up to AE
Source of research
funding
Journal
Perrone et al.
2014, Italy [29]
To determine the
prevalence, preventability,
seriousness requiring
hospitalization,
subsequent 30-day
mortality, and economic
impact of ADRs
presenting to multiple EDs
serving a large proportion
of the Lombardy region
over a 2-year period
Patients (n = 8,862)
presenting to the ED with
ADR (mean age, years±
SD 55.9 (24.3), male sex
44.3%)
Retrospective cohort
study
2 years NA Regional
Pharmacovigilance
Centre of Lombardy,
Italian Medicines
Agency (AIFA)
Clinicoeconomics and
Outcomes Research
Other
prospective and
retrospective
observational
studies
Jamunarani and
Priya 2014, India
[30]
To see the clinical
spectrum of ADR related
hospital admissions in a
tertiary care hospital, to
establish a causal link
between the drug and
reaction, and to identify
common challenges
encountered in ADR
collection process and
methods to promote ADR
reporting
Patients hospitalized due
to ADRs (n = 33, mean
age NR, male sex 45.5%)
Cross sectional
analytical study
1 year 1
month
NA NR Asian Journal of
Pharmaceutical and
Clinical Research
Llop et al. 2017,
USA� [25]
To investigate real-world
outcomes and costs
associated with the use of
current guideline-
recommended
antimicrobial treatments
for CAP in both the
outpatient and inpatient
settings
Outpatients (n = 165,768,
age, years 53.1 ± 16.4,
male sex 51.0%)
diagnosed with CAP and
treated with FQ,
macrolide (n = 169,335,
age, years 47.4 ± 16.8,
male sex 48.0%) or beta-
lactam (n = 36,702, age,
years 51.7 ± 18.1, male
sex 49.1%)
Claims-based
retrospective study
6 years 30 days Cempra
Pharmaceuticals
Hospital Practice
Martı´ et al. 2005,
Spain [31]
To ascertain the
epidemiological
characteristics, clinical
symptoms, and evolution
of drug-induced hepatitis
over 22 years
Inpatients and
outpatients with a
diagnosis of drug-
induced hepatitis (n = 61,
mean age, years ± SD 52.4
(17), male sex 42.6%)
Retrospective
observational study
and prospective study
22 years NA NR Revista Española de
Enfermedades Digestivas
Mjo¨rndal et al.
2002, Sweden
[32]
To determine the
occurrence and pattern of
ADRs as a cause for acute
admission into a clinic of
internal medicine
Patients (n = 82, median
age, years (range) 74 (21–
92), male sex 46.3%)
admitted to hospital due
to ADR compared with
patients (n = 587, median
age, years (range) 72 (19–
97), male sex 49.1%)
admitted to hospital due
to other causes
Prospective study 36 weeks NA The Federation of
Swedish County
Councils
Pharmacoepidemiology
and Drug Safety
(Continued)
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([23][32][35][29]). Mjo¨rndal et.al. [32] and Perrone et.al. [29] specifically stated that costs con-
sist of direct hospital costs. Llop et.al.[25] did not specify cost details beyond costs associated
with AEs and retreatment. None of the included studies reported travel or time costs, indirect
costs or specified the payer.
Table 2. (Continued)
Study, Year of
publication,
Country
Aim of the Study Patients Study design Study
duration
Follow-
up to AE
Source of research
funding
Journal
Noel et al. 2004,
India [33]
To evaluate the clinical
spectrum of all cutaneous
ADRs over one year in
hospitalized patients in the
Department of
Dermatology and the
establish the causal link
between the suspected
drug and the reaction by
using the WHO causality
definitions
Patients admitted to the
Department of
Dermatology diagnosed
with cutaneous ADRs
(n = 56, mean age
unclear, male sex 50%)
Prospective hospital-
based study
1 year NA NR Indian Journal of
Pharmacology
Olivier et al.
2002, France [34]
To assess the incidence
and the preventability of
ADR-related admissions
and to assess the feasibility
of a wider use of a
preventability scale in
clinical practice
Patients presenting to an
ED with a suspected ADR
(n = 41, mean age,
years ± SD 58 (22.2), male
sex 54%) compared with
patients presenting to an
ED for other reasons than
suspected ADR (n = 630,
mean age, years ± SD 55.6
(22.5), male sex 55%)
Prospective
pharmacovigilance
study
4 weeks NA No funding to disclose Drug Safety
Patel et al. 2007,
India [35]
To evaluate the prevalence
of patients presenting with
ADRs to the ED and to
assess the causality,
avoidability, and severity
of ADRs. The study also
aimed to determine the
economic burden of ADRs
from a hospital
perspective.
Patients (n = 265, mean
age, years 40, male sex %
unclear) admitted to ED
due to ADRs.
Prospective
observational study
6 weeks NA NR BMC Clinical
Pharmacology
Sa´nchez Muñoz-
Torrero et al.
2010, Spain [36]
To assess the prevalence of
ADRs in the internal
medicine wards of two
teaching hospitals, identify
the most common ADRs,
the principal medications
involved, and determine
the risk factors implicated
in the occurrence of such
ADRs
Patients admitted to
hospital with ADRs
(n = 126, median age,
years (range) 69 (16–97),
male sex 47%) compared
with patients admitted to
hospital without ADRs
(n = 279, median age,
years (range) 67 (15–102),
male sex 54%)
Prospective
observational study
10 weeks NA NR European Journal of
Clinical Pharmacology
Su and Aw 2014,
Singapore [37]
To look at the
epidemiology of SCAR in
the local setting in
Singapore and the
underlying characteristics
of our patients that may
influence the drug
reaction seen
Inpatients (n = 42), mean
age 51.8 years, male sex
50%
Retrospective study 5 years NA NR International Journal of
Dermatology
AE, adverse event; ADE, adverse drug event; ADR, adverse drug reaction; CAP, community-acquired pneumonia; CDAD, Clostridium difficile-associated disease; CDI,
clostridium difficile infection; cipro, ciprofloxacin; ED, emergency department; FQ, fluoroquinolone; gati, gatifloxacin; IQR, interquartile range; levo, levofloxacin;
moxi, moxifloxacin; NA, not applicable, NR, not reported; SCAR, severe cutaneous adverse reaction
https://doi.org/10.1371/journal.pone.0216029.t002
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Differences in adverse events according to various fluoroquinolones
Levofloxacin[20]-[27][30][25][28][29][36] and ciprofloxacin [20][22]-[27][38][32][33][35]
[36][37] were the most frequently utilized interventions (Table 3), with both being included in
12 studies. In these studies, levofloxacin was associated with various AEs, including dysglyce-
mia, CDAD, hepatotoxicity, diarrhea, altered mental status, rash and thrush. AEs associated
with ciprofloxacin included dysglycemia, CDAD, hepatotoxicity, hepatitis, Stevens-Johnson
Syndrome (SJS), acute generalized exanthematous pustulosis (AGEP), increased prothrombin
complex, seizures, diarrhea, rash and fever. Moxifloxacin was included in four studies[20][21]
[24][26] and associated with dysglycemia, CDAD and hepatotoxicity. Norfloxacin[31] was
present in one study and linked to hepatitis. Ofloxacin use was reported in five studies [30][38]
[33]-[35] and linked to an epileptic seizure, urticarial lesion, fixed drug effect, exfoliative der-
matitis, angioedema and photodermatitis (PD).
In the included studies, norfloxacin and ofloxacin were associated with the least reports of
health service use and costs. Conversely, levofloxacin and ciprofloxacin, the most frequently
considered FQs, appeared to be connected to the most AEs, health service use and costs.
Health service use and health service costs associated with FQ-related AEs are depicted in
Table 3.
The quality of the included studies
The results of the quality assessment are illustrated in Fig 2. The included studies scored an
average 19.74 and median 20 (range 10 and 27) points out of 34 total points. The weighted
average rating was 65% (range 36–84%). Although the scores are relatively high, some inade-
quacies were apparent in reporting. Only six studies described efforts to address potential
sources of bias ([20]-[22][24][26][27]). Two studies provided an explanation for the popula-
tion sample size ([22][34]).
Seven studies failed to report the funding of the study ([30][38][31][33][35][36][37]). The
case-controlled observational studies all reported the source of research funding but otherwise
there was no difference in the results of the quality assessment regarding study design. The ful-
fillment of the STROBE checklist items is portrayed in S1 Table.
Discussion
The aim of this systematic review was to identify health service use and costs associated with
FQ-related AEs. To date, research concentrating on costs associated with drug-related AEs
remains scarce. As far as we know, the economic impacts of any FQ-related AEs have previ-
ously not been examined in a systematic review. Due to the substantial gap in published
literature, we were unable to examine many serious and costly FQ-related AEs, such as neuro-
psychiatric AEs, QT interval prolongation, aortic aneurysm and tendinopathy in this review.
There was considerable heterogeneity among the included studies. The most variation was
associated with population sample sizes (n = 33–1,277,248) and study duration (4 weeks—22
years) as well as AEs considered. Although randomized controlled trials (RCTs) were not
excluded from the literature search, all the included studies were observational. Observational
studies may pick up on AEs not observed in RCTs, which might be due to several factors.
RCTs frequently exclude patients who are most vulnerable to AEs, such as the elderly and
patients with comorbidities. In addition, sample sizes are in many cases smaller and follow-up
periods often shorter in RCTs than in observational studies. Of the 19 studies included in the
review, five were case-controlled, in order to explicitly observe risk rates of AEs associated
with FQs. Even then, the number of FQ-related AEs assessed in the included studies in propor-
tion to the population size was small, which could mean that all FQ-related AEs were not
FQ-related AEs resulting in health service use and costs
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Table 3. Health service use and costs associated with FQ-related AEs.
AE type Study Intervention
(s) relevant to
study
Reported FQ AE AE occurence Fatalities in
study
associated
with any AE
AE-related health
service use
Length of hospital
stay
AE costsa
Dysglycemia Aspinall et al.
(2009) [27]
Levo, cipro N = 212
Hypoglycemia: levo n = 86,
cipro n = 19;
hyperglycemia: levo n = 84,
cipro n = 23
Incidence per 1,000
patients:
Hypoglycemia: levo
0.19 (95% CI 0.15–
0.23), cipro 0.10
(0.06–0.15),
hyperglycemia: levo
0.18 (0.15–0.23), cipro
0.12 (0.08–0.18)
None
reported
Hospitalization NR NR
Chou et al
(2013) [26]
Cipro, levo,
moxi
N = 375
Hypoglycemia: cipro
n = 99, levo n = 109, moxi
n = 42; hyperglycemia:
cipro n = 50, levo n = 46,
moxi n = 29
Incidence per 1,000
patients:
Hypoglycemia: cipro
7.88, levo 9.26, moxi
9.95, hyperglycemia:
cipro 3.98, levo 3.91,
moxi 6.87
None
reported
ED visit or
hospitalization
Median, days,
hypoglycemia:
cipro 15, levo 9,
moxi 14;
hyperglycemia:
cipro 12, levo 10,
moxi 13
NR
CDAD Dhalla et al.
(2006)[20]
Levo, cipro,
moxi
N = 88
Levo n = 28, cipro n = 44,
moxi n = 16
OR (95% CI): Levo
(reference) 1.00, cipro
0.85 (0.52–1.41), moxi
1.18 (0.61–2.27)
N = 16
(16,7%)
Hospitalization Median 12 days
(IQR 6–23)
NR
Mah et al.
(2011) [28]
Levo N = 66 2.5% N = 10/202
(5%) died or
had a
colectomy
Hospitalization NR NR
McFarland
et al. (2007)
[22]
Levo, cipro N = 41
Levo n = 33, cipro n = 8
Unclear N = 54
(15%)
Hospitalization: 30%
required ICU and
21% readmission to a
health care facility <1
year after hospital
discharge, 2% of
patients required
gastrointestinal
surgery
Total mean
days ± SD 45.2
(6.3)
NR
Muto et al.
(2005) [23]
Levo, cipro N = 135
Levo n = 120, cipro n = 15
Levo OR (95% CI) 2.0
(1.2–3.3)
N = 18 Hospitalization NR 3,571
€/episode,
health care
costs due to
CDAD
outbreak
2000–2001
903,407 €
Liver injury
or hepatitis
Kaye et al.
(2014) [21]
Levo, moxi N = 175
Liver injury associated
with levo within 30 days of
exposure n = 58, moxi
n = 30, liver injury
associated with levo within
90 days of exposure n = 57,
moxi n = 25, liver failure
levo n = 5
Liver injury incidence
per 100,000 person-
years associated with
levo within 30 days of
exposure 134.3, moxi
116.4, incidence
associated with levo
within 90 days of
exposure 70.9, moxi
52.6
N = 32
(5.3%)
Hospitalization, ED
visit
NR NR
Martı´ et al.
(2005) [31]
Nor Hepatitis n = 2 Unclear None
reported
Hospitalization NR NR
Paterson
et al. (2012)
[24]
Cipro, levo,
moxi
N = 121
Hepatotoxicity associated
with cipro n = 67, levo
n = 28, moxi n = 26
Incidence per 100,
000 exposures cipro:
6.37, levo: 8.62, moxi:
7.89
N = 88
(61.1%)
Hospitalization Median 8 (IQR
4–16) days
NR
(Continued)
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Table 3. (Continued)
AE type Study Intervention
(s) relevant to
study
Reported FQ AE AE occurence Fatalities in
study
associated
with any AE
AE-related health
service use
Length of hospital
stay
AE costsa
Seizure Olivier et al.
(2002) [34]
Oflo Epileptic seizure n = 1 Unclear None
reported
Hospitalization 10 days NR
Cutaneous
AEs
Jamunarani
and Priya
(2014) [30]
Levo, oflo Maculopapular eruption
(levo), urticarial lesion
(oflo), fixed drug effect
(oflo), exfoliative dermitis
(oflo), angioedema (oflo),
n = 8
Unclear None
reported
Hospitalization < 5 days 21.2%,
5–20 days 63.6%,
> 20 days 15.2%
NR
Noel et al.
(2004) [33]
Cipro, Oflo N = 2
SJS (cipro n = 1), PD (oflo
n = 1)
Unclear None
reported
Hospitalization NR NR
Su and Aw
(2014)[37]
Cipro SJS, AGEP n = 2 Unclear N = 1 Hospitalization SJS: 34 days,
AGEP: 16 days
NR
Several
reported
AEs
Llop et al.
(2017) �[25]
Levo (68%),
other FQ
(32%)
N = 26,893
Clostridium difficile
infection and enterocolitis
n = 122, peripheral
neuropathy n = 375,
tendinitis n = 1,326,
digestive effects n = 5,667,
CNS effects n = 14,951,
skin reactions n = 2,516,
hepatotoxicity n = 543,
hematologic toxicity
n = 6,540
16.2% None
reported
Hospitalization NR Unadjusted
costs of AE
4,528 € ±
18,252 €
Mjo¨rndal
et al. (2002)
[32]
Cipro N = 2
Increased prothrombin
complex n = 1, seizures
n = 1
Unclear N = 2 Hospitalization 6 (0–30) days Average cost of
treating one
person with
ADR 2,700 €
Patel et al.
(2007)[35]
Cipro, Oflo Complex partial seizures,
peripheral neuropathy,
dystonia, hypersensitivity
reaction, tendinitis,
dysgeusia; n = unclear
Unclear N = 17
(0.83%)
Hospitalization Median 5 days
(95% CI 5.37–
7.11)
Average cost
per patient
hospitalized
140 €
Sa´nchez
Muñoz-
Torrero et al.
(2010) [36]
Levo, cipro N = 32
Diarrhea (levo n = 17,
cipro n = 4),
pseudomembranous colitis
(levo n = 2), altered mental
status (levo n = 1), rash
(levo n = 1, cipro n = 1),
thrush (levo n = 4),
hepatitis (cipro n = 1),
fever (cipro n = 1)
Unclear N = 2
(1,6%)
Hospitalization Median 18 ±17
days
NR
Non-
specified
AEs
Jayarama
et al. (2012)
[38]
Cipro, Oflo N = 3
Cipro n = 2, oflo n = 1
Unclear None
reported
ED visit NA NR
Perrone et al.
(2014) [29]
Levo N = 172 Unclear 1,5% ED visit NA Mean 592 € ±
2,175 € /
patient
� Out-patient analysis; AE, adverse event; AGEP, acute generalized exanthematous pustulosis; CDAD, clostridium difficile-associated diarrhea; cipro, ciprofloxacin; ED,
emergency department; FQ, fluoroquinolone; levo, levofloxacin; moxi, moxifloxacin; nor, norfloxacin; NA, not applicable; NR, not reported; oflo, ofloxacin; OR, odds
ratio; SD, standard deviation; SJS, Stevens-Johnson syndrome
aAll costs converted into 2016 euro
https://doi.org/10.1371/journal.pone.0216029.t003
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assessed. In 13 studies[20]-[24][26]-[30][28][31][33][34][37], only specific AEs were exam-
ined and many AEs may not have been reported or even recognized. Of the five FQs in this
study, levofloxacin was associated with the most reported AEs, health service use, length of
hospital stay and costs. Ciprofloxacin was associated with similar AEs, health service use,
length of stay and costs as levofloxacin, but with smaller volume. Norfloxacin, on the other
hand, was only linked to two cases of hepatitis. These data do not allow comparisons across
FQs and drawing of definite conclusions relating to health service use and costs associated
with levofloxacin, ciprofloxacin, moxifloxacin, norfloxacin and ofloxacin. Levofloxacin and
ciprofloxacin were considered in 12 studies, including extremely large studies, and norfloxacin
in only one. Therefore, the number of AEs associated with specific FQs reported in the studies
is related to the utilization of the FQ and not necessarily to the toxicity. At present ciprofloxa-
cin followed by levofloxacin are the most consumed FQs globally[39][40]. Previous research
has shown that the safety profiles of the FQs included in this systematic review are similar to
each other[1].
In this systematic review, hospitalizations and ED visits were the main health service use
outcomes associated with AEs. Outpatient visits to primary care facilities were not reported in
Fig 2. Quality assessment of the included studies. The included studies were assessed according to STROBE checklist and awarded scores, which are
presented in percentages.
https://doi.org/10.1371/journal.pone.0216029.g002
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the included studies, although it is likely that most AEs are diagnosed and treated in primary
care, if recognized as FQ-related at all. According to prior research by Magdelijns et.al., hospi-
talizations, specifically long stays in hospital, are the leading cost drivers in health service use.
Hospitalizations were estimated to cause approximately 77% of direct health care costs associ-
ated with AEs in the Netherlands[41].
Reported FQ-related AE-costs varied between 140 and 18,252€ per AE episode. CDAD was
associated with the largest amount of health service use, longest stays in hospital and, thus, the
highest reported costs of AEs considered. Mean CDAD-related length of stays were up to 45
days. Since the emergence of the epidemic Clostridium difficile ribotype 027 clone, CDAD has
become more prevalent, severe and more difficult to treat, due to resistance to many antimi-
crobial agents[42]. The included studies took only into account the direct treatment costs,
which does not represent the total costs of a FQ-related AE episode. Evaluating all AE-trig-
gered costs, regardless of who they fall on, would reflect a more accurate assessment. However,
as described in Table 2, the aims of the included studies did not involve examining health ser-
vice use or costs. Therefore, both health service use and costs were addressed in a cursory man-
ner and were likely underestimated. In the five studies that did report costs ([23][25][32][35]
[29]), they proved difficult to compare. Costs relating to healthcare systems, diagnostic meth-
ods and treatment protocols differ significantly depending on the origin of the study and the
AEs considered. In addition, the severity of the reported FQ-related AEs may have fluctuated
and resulted in diverse health service use and costs. AE-related costs, when reported, lack ade-
quate transferability. Conversely, health service use and length of hospital stay are outcomes
that can be more effectively compared and transferred, regardless of the origin of the study.
Even here, temporal, geographical and payer differences may lead to disparities in these met-
rics for similar AEs.
Limitations of this systematic review include confining the literature search to full English
language texts. However, the risk of lost key findings is minor due to the paucity of non-
English texts excluded from the review. In addition, we excluded studies with pediatric
patients, though inclusion could have led to added information about health service use and
costs. The use of FQs in children continues to be limited or restricted. Although studies have
described the majority of FQ-related AEs in pediatric patients as temporary and reversible[43],
real-world safety data continue to be scarce. We acknowledge that the use of STROBE checklist
for observational studies is not recommended for assessing the methodological quality of stud-
ies. There is a distinct deficiency of reliable, comprehensive and validated tools for the quality
assessment of observational studies. We did not exclude any studies due to poor quality and
therefore using STROBE did not introduce bias into this systematic review. Additionally, there
is a lack of guidelines and definitions regarding data quality, which is not addressed in quality
assessments. This could potentially cause bias. The shortage of existing research relating to
health service use and costs associated with FQ-related AEs and the incomplete nature of AEs
considered in those that do report these, account for the largest limitation of this systematic
review. Funding, in addition to the undetection and underreporting of AEs are issues that can
restrict and direct studies. Present means and resources available to allow independent AE-
research are poor.
Conclusions
Because of the wide clinical use of FQs, in particular serious FQ-related AEs can have substan-
tial economic implications, in addition to imposing potentially long-lasting health complica-
tions for patients. Better-quality reporting and additional published data on health service use
and costs associated with AEs are both necessary and overdue.
FQ-related AEs resulting in health service use and costs
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